Pacira BioSciences Inc. announced it has entered into an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension) in select Asian-Pacific markets. Under the terms of the agreement, Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales made by LG Chem in the licensed territories. Pacira will manufacture EXPAREL, while LG Chem will be responsible for obtaining regulatory approvals and plans to file for marketing authorizations in South Korea and Thailand within the next six months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624180-en) on January 13, 2026, and is solely responsible for the information contained therein.